CA-DENODO
27.10.2021 09:02:12 CEST | Business Wire | Press release
Denodo , the leader in data virtualization, today announced that its annual global user conference, Denodo DataFest 2021 , which was held in North America (NA), EMEA and APAC, attracted 5,000 worldwide registrants. While DataFest APAC and EMEA were held in a virtual format this year, DataFest NA was conducted in a hybrid mode, attracting hundreds of attendees online and in-person in New York. The attendees, made up of Denodo customers, partners, and subject matter experts, discussed the future of data and analytics involving topics such as logical data fabric, cloud modernization, data mesh, AI/ML and more.
Forrester VP and Principal Analyst Michele Goetz kicked off the conference presenting the Total Economic Impact™ of Data Virtualization using Denodo Platform , while David Loshin, President of Knowledge Integrity at TDWI presented the importance of Logical Data Fabric for Hybrid Cloud. Click here to watch the full conference line up.
“While we are not entirely over the pandemic yet, I was personally touched and thrilled to see the excitement among our customers and partners, both in-person and online who joined us to make this year’s DataFest such a success,” said Ravi Shankar, SVP and CMO at Denodo. “Our customers, partners, and internal subject matter experts presented and discussed topics such as why data lakehouse needs a logical architecture, application of advanced semantics in multi/hybrid cloud scenarios, the need for performance acceleration for advanced analytics and data science, to name a few. It was great to see the strength of our customers’ use cases as the Innovation Award polling saw stiff competition among the finalists.”
Winners and Finalists of Denodo Data Innovation Awards 2021 include:
- North America – Winner Ryan Fattini from City Furniture , for their Digitizing City Furniture’s Business Model use case; finalist Jonathan Paul from Fifth Third Bank , for their Digital Transformation and Regulatory Excellence use case.
- APAC – Winner Shaurya Bhasin from GeTS , for their Logical Data Fabric use case; finalist Wilbertus Darmadi from Toyota Astra Motor , for their Data Catalog based Self-Service use case.
- EMEA – Winner Jan Swanepoel from NedBank , for their Largest Data Warehouse on the Planet use case; finalist, Luis Guadarrama from Engie for their data-driven initiatives with Logical Data Fabric use case.
“Winning this year’s Data Innovation Award for the APAC region was a great validation of the strength of our data virtualization use cases and the results we were able to achieve,” said Shaurya Bhasin, Data Platform Lead at GeTS. “In building our unified data platform we were able to offer secure and well governed data access in a multi-cloud scenario. The Denodo Platform is as an important piece of the architecture and I was happy to share our story with the DataFest audience and perhaps it resonated with the audience!”
While Denodo customers played a pivotal role in sharing their business and technical use cases with the audience, it was the amazing network of Denodo Partners which included Accenture, Advanced Analytic Service, Axians, BDO (SimplicityBI), BITanium, CIO Academy Asia (CIOAA), Cognizant, Cyberionix, Dai Nippon Printing, DAMA, Devfacto, EY, Hitachi Solutions, Indium Software, Insight Technology, iOCO, IQZ Systems, JEMS, Mainline, MDI Novare Technologies, Nippon Systemware, NS Solutions, Nucleus Software, Q Perior, Servian, Sirius, UST, Wipro and Zeal that made an event of this scale possible. Denodo’s technology partner AWS took part in a Fireside chat to discuss the important of Logical Data Fabric for successful cloud migration.
Please tweet: #datavirtualization leader Denodo announce the winners of 4th annal Data Innovation Awards During #DataFest 2021. Audience vote @CityFurniture, @CLGeTS and @Nedbank for the most innovative use cases
About Denodo
Denodo is the leader in data virtualization providing agile, high performance data integration, data abstraction, and real-time data services across the broadest range of enterprise, cloud, big data, and unstructured data sources at half the cost of traditional approaches. Denodo’s customers across every major industry have gained significant business agility and ROI by enabling faster and easier access to unified business information for agile BI, big data analytics, Web, cloud integration, single-view applications, and enterprise data services. Denodo is well-funded, profitable, and privately held. For more information, visit http://www.denodo.com or call +1 877 556 2531 / +44 (0) 20 7869 8053.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211027005047/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom